The widened net loss and increased expenses indicate financial pressure, which could concern investors. However, the strong cash position may provide some reassurance. The decrease in revenue and the significant investment in R&D and SG&A for obicetrapib's potential launch are critical factors. These elements suggest a short-term negative impact on the stock price, as the market may focus on the increased losses and expenses before any potential long-term benefits from obicetrapib.